The Chinese-German Journal of Clinical Oncology

, Volume 9, Issue 9, pp 502–506

Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases

  • Fang Wang
  • Liangping Xia
  • Guifang Guo
  • Huijuan Qiu
  • Feifei Zhou
  • Bei Zhang
  • Li Zhang
Article

Abstract

Objective

Cetuximab combined with chemotherapy has been used to treat non-small cell lung cancer (NSCLC) in recent years, most of them were first line setting. This study was to summarize our experiences in treating NSCLC patients with cetuximab in the non-first line setting.

Methods

From October 1st 2006 to December 31st 2009, six NSCLC patients were treated with cetuximab combined standard chemotherapy as non-first line setting in Sun Yat-sen University Cancer Center, China. The short-term efficacies and safeties were analyzed.

Results

1. A total of 18 cycles of cetuximab treatment, with a median of two cycles in the whole group. 2. There were 6 patients treated as non-first line setting, overall response rate (ORR) was 33.3% (2/6), disease control rate (DCR) was 33.3% (2/6), median time to progression (TTP) was 3.5 (3–4) months, and median OS was 18 (4–28) months. 3. There were 50% (3/6) patients occurred acne-like rash within three weeks, their ORR was 66.7% (2/3), and DCR was 66.7% (2/3), however, both of ORR and DCR in patients who didn’t occurred acnelike rash were 0% (0/3), the differences of ORR, DCR between two groups were insignificant different (P = 0.143). 4. There was no treatment-associated death and no cetuximab-associated discontinuation. The incidence of acne-like rash was 50% occurred within three weeks, there were two patients suffered side effects associated with chemotherapy.

Conclusion

The data of cetuximab application in non-first line setting for patients with NSCLC were rare, and the addition of cetuximab in those population was safe.

Key words

cetuximab non-small cell lung cancer (NSCLC) efficacy safety non-first line 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361: 958–967.CrossRefPubMedGoogle Scholar
  2. 2.
    Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361: 947–957.CrossRefPubMedGoogle Scholar
  3. 3.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353: 123–132.CrossRefPubMedGoogle Scholar
  4. 4.
    Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 2006, 1: 847–855.CrossRefPubMedGoogle Scholar
  5. 5.
    Cappuzzo, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. ECCO ESMO, 2009.Google Scholar
  6. 6.
    Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol, 2008, 26: 427s(LBA8012).Google Scholar
  7. 7.
    Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet, 2009, 373: 1525–1531.CrossRefPubMedGoogle Scholar
  8. 8.
    Socinski MA, Saleh MN, Trent DF, et al. A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). Ann Oncol, 2009, 20: 1068–1073.CrossRefPubMedGoogle Scholar
  9. 9.
    Belani CP, Schreeder MT, Steis RG, et al. Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer, 2008, 113: 2512–2517.CrossRefPubMedGoogle Scholar
  10. 10.
    Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 2007, 25: 5777–5784.CrossRefPubMedGoogle Scholar
  11. 11.
    Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23: 9089–9096.CrossRefPubMedGoogle Scholar
  12. 12.
    Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol, 2005, 23: 8786–8793.CrossRefPubMedGoogle Scholar
  13. 13.
    Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol, 2010, 28: 911–917.CrossRefPubMedGoogle Scholar
  14. 14.
    Thatcher N, Linchy TJ, Butts CA, et al. Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trails. WCLC 2009, oral presentation (abstract A3.7).Google Scholar
  15. 15.
    Lin H, Jiang J, Liang X, et al. Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Lung Cancer, 2010 Feb 9 [Epub ahead of print].Google Scholar
  16. 16.
    Xia LP, Rong YM, Guo GF, et al. The summary of efficacy of cetuximab combination with chemotherapy in NSCLC first-line setting: based on publication. Chinese-German J Clin Oncol, 2010, 9: 137–141.CrossRefGoogle Scholar
  17. 17.
    Kim ES, Mauer AM, William WN Jr, et al. A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall-cell lung cancer. Cancer, 2009, 115: 1713–1722.CrossRefPubMedGoogle Scholar
  18. 18.
    Hanna N, Lilenbaum R, Ansari R, et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol, 2006, 24: 5253–5258.CrossRefPubMedGoogle Scholar
  19. 19.
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol, 2008, 26: 3543–3551.CrossRefPubMedGoogle Scholar
  20. 20.
    Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355: 2542–2550.CrossRefPubMedGoogle Scholar
  21. 21.
    Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol, 2009, 27: 1227–1234.CrossRefPubMedGoogle Scholar
  22. 22.
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000, 18: 2095–2103.PubMedGoogle Scholar
  23. 23.
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 2004, 22: 1589–1597.CrossRefPubMedGoogle Scholar
  24. 24.
    Smit EF, Burgers SA, Biesma B, et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2009, 27: 2038–2045.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang YF, Chen ZW, Lu S. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer. Chin Med J (Engl), 2009, 122: 2472–2476.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Fang Wang
    • 1
    • 2
  • Liangping Xia
    • 1
    • 2
  • Guifang Guo
    • 1
    • 2
  • Huijuan Qiu
    • 1
    • 2
  • Feifei Zhou
    • 1
    • 2
  • Bei Zhang
    • 1
    • 2
  • Li Zhang
    • 1
    • 3
  1. 1.State Key Laboratory of Oncology in South ChinaGuangzhouChina
  2. 2.VIP RegionSun Yat-sen University Cancer CenterGuangzhouChina
  3. 3.Department of Medical OncologySun Yat-sen University Cancer CenterGuangzhouChina

Personalised recommendations